



Atara Biotherapeutics  
Investor Relations Department  
701 Gateway Blvd, Suite 200  
South San Francisco, CA 94080  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ATRA

Last Trade:	14.30
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	-0.25 <span style="color: red;">▼</span> (-1.718%)
Day Range	14.15 - 14.75
52-Week Range	11.80 - 23.00
Volume	95,367


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company's stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-... [\(more\)](#))

## Stock Performance



## Press Releases [\[ View all \]](#)

Oct 16, 2017

[Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis \(MS\)](#)

Sep 11, 2017

[Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129](#)

Sep 5, 2017

[Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230](#)

Aug 31, 2017

[Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences](#)

## Upcoming Events [\[ View all \]](#)

Oct 25–28, 2017

[MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis \(ECTRIMS\) and the Americas Committee for Treatment and Research in Multiple Sclerosis \(ACTRIMS\)](#)

Nov 15–16, 2017

[Jefferies 2017 London Healthcare Conference](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)